VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
VBI Vaccines Inc. (Nasdaq: VBIV) announces participation in the Raymond James 42nd Annual Institutional Investors Conference on March 2, 2021. CEO Jeff Baxter and CSO David E. Anderson, Ph.D., will present from 4:40 PM to 5:20 PM ET. The event will highlight the company's innovative approach to vaccine development using virus-like particles to combat diseases such as hepatitis B and coronaviruses. A live webcast of the presentation will be available, with a recording accessible on the company's website afterward.
- None.
- None.
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021, at 4:40 PM ET.
Presentation Details:
- Event: Raymond James 42nd Annual Institutional Investors Conference
- Presenters: Jeff Baxter, President and CEO, and David E. Anderson, Ph.D., Chief Scientific Officer
- Date: Tuesday, March 2, 2021
- Time: 4:40 – 5:20 PM ET
- Webcast: https://kvgo.com/rjinstitutionalinvestors/vbi-vaccines-inc-march-2021
A recording of the webcast will be available on the “Events and Presentations” page of the Company’s website: https://www.vbivaccines.com/investors/events-and-presentations/.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
Website Home: http://www.vbivaccines.com/
News and Resources: http://www.vbivaccines.com/news-and-resources/
Investors: http://www.vbivaccines.com/investors/
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005295/en/
FAQ
What is VBI Vaccines' participation in the Raymond James Conference 2021?
Who will represent VBI Vaccines at the conference?
Where can I watch the VBI Vaccines presentation from the conference?
What is the focus of VBI Vaccines' research?
What technology does VBI Vaccines use in its vaccine development?
